5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer

(2010) Anna Novarino et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)

(2010) L. Dahan et al.   GUT

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

(2009) C Yoo et al.   BRITISH JOURNAL OF CANCER

Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study

(2009) Brett E. Fortune et al.   ONCOLOGY

Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

(2009) Uwe Pelzer et al.   Oncology Research and Treatment

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

(2008) Henry Q. Xiong et al.   CANCER

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

(2008) Seong Yoon Yi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY